GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JCR Pharmaceuticals Co Ltd (TSE:4552) » Definitions » Debt-to-Asset

JCR Pharmaceuticals Co (TSE:4552) Debt-to-Asset : 0.23 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is JCR Pharmaceuticals Co Debt-to-Asset?

JCR Pharmaceuticals Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円9,700 Mil. JCR Pharmaceuticals Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円13,600 Mil. JCR Pharmaceuticals Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was 円102,773 Mil. JCR Pharmaceuticals Co's debt to asset for the quarter that ended in Dec. 2023 was 0.23.


JCR Pharmaceuticals Co Debt-to-Asset Historical Data

The historical data trend for JCR Pharmaceuticals Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JCR Pharmaceuticals Co Debt-to-Asset Chart

JCR Pharmaceuticals Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.25 0.19 0.24 -

JCR Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.24 0.22 0.23 -

Competitive Comparison of JCR Pharmaceuticals Co's Debt-to-Asset

For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JCR Pharmaceuticals Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where JCR Pharmaceuticals Co's Debt-to-Asset falls into.



JCR Pharmaceuticals Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

JCR Pharmaceuticals Co's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

JCR Pharmaceuticals Co's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JCR Pharmaceuticals Co  (TSE:4552) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


JCR Pharmaceuticals Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of JCR Pharmaceuticals Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


JCR Pharmaceuticals Co (TSE:4552) Business Description

Traded in Other Exchanges
Address
3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.

JCR Pharmaceuticals Co (TSE:4552) Headlines

No Headlines